Inspire Medical Systems, Inc. (INSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - The company preannounced its Q4 and full year revenue, indicating continued growth and adoption of the Inspire V system [1] - Initial revenue guidance for 2026 is projected at 10% to 11% growth, consistent with previous indications [1] - Recent reimbursement developments are viewed positively, although initial revenue guidance does not include contributions from these changes [2] Revenue and Guidance - The revenue guidance for 2026 reflects a growth rate of 10% to 11%, aligning with prior earnings call indications [1] - The procedure code 64568 has been associated with the Inspire V since FDA approval in 2014 and was billed for procedures throughout 2025 [2] - A software update on July 1 was crucial for the launch of the Inspire V device [2]